Osteopontin is a drug commonly used in chronic renal failure. Its main function is to promote calcium absorption. In renal failure, there will be disorders of calcium and phosphorus metabolism and hyperparathyroidism, so exogenous supplementation of osteopontin can, firstly, prevent hypocalcemia and, secondly, antagonize the increase of parathyroid hormone, thus preventing renal bone disease. The main side effect of osteoinol is that it can lead to hypercalcemia and hyperphosphatemia. Further vascular calcification can occur, so it is not indicated in cases of hypercalcemia and hyperphosphatemia, and when the calcium-phosphorus product is greater than 65, which can lead to a significantly increased risk of cardiovascular disease.